Abstract:Objectives This study was designed to assess the clinical course and to identify risk factors for life-threatening events in patients with long-QT syndrome (LQTS) with normal corrected QT (QTc) intervals.Background Current data regarding the outcome of patients with concealed LQTS are limited.Methods Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SCD) from birth through age 40 years were examined in 3,386 genotyped subjects from 7 multinational LQTS registries, categorized as LQTS with normal-range QTc (<= 440 ms [n = 469]), LQTS with prolonged QTc interval (>440 ms [ n = 1,392]), and unaffected family members (genotyped negative with <= 440 ms [ n = 1,525]).Results The cumulative probability of ACA or SCD in patients with LQTS with normal-range QTc intervals (4%) was significantly lower than in those with prolonged QTc intervals (15%) (p < 0.001) but higher than in unaffected family members (0.4%) (p < 0.001). Risk factors ACA or SCD in patients with normal-range QTc intervals included mutation characteristics (transmembrane-missense vs. nontransmembrane or nonmissense mutations: hazard ratio: 6.32; p = 0.006) and the LQTS genotypes (LQTS type 1: LQTS type 2, hazard ratio: 9.88; p = 0.03; LQTS type 3: LQTS type 2, hazard ratio: 8.04; p = 0.07), whereas clinical factors, including sex and QTc duration, were associated with a significant increase in the risk for ACA or SCD only in patients with prolonged QTc intervals (female age >13 years, hazard ratio: 1.90; p = 0.002; QTc duration, 8% risk increase per 10-ms increment; p = 0.002).Conclusions Genotype-confirmed patients with concealed LQTS make up about 25% of the at-risk LQTS population. Genetic data, including information regarding mutation characteristics and the LQTS genotype, identify increased risk for ACA or SCD in this overall lower risk LQTS subgroup. (J Am Coll Cardiol 2011;57:51-9) (C) 2011 by the American College of Cardiology Foundation

Lqts Gene Lovd Database

Identification of A Kir3.4 Mutation in Congenital Long Qt Syndrome

[Clinical Practice Guidelines for Long Q-T Interval Syndrome].

Association of Ion Channel Genes KCNQ1 and KCNH2 with Congenital Long-QT Syndrome

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

[Novel Mutations of Potassium Channel KCNQ1 S145L and KCNH2 Y475C Genes in Chinese Pedigrees of Long QT Syndrome].

Risk for Life-Threatening Cardiac Events in Patients with Genotype-Confirmed Long-Qt Syndrome and Normal-Range Corrected QT Intervals.

KCNQ1 and KCNH2 Mutations Associated with Long QT Syndrome in a Chinese Population.

PO-630-04 ELUCIDATION OF ALG10B AS A NOVEL LONG QT SYNDROME SUSCEPTIBILITY GENE

Long QT Syndrome Diagnosed by Genetic Analysis in Six Pedigress

Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Α-1-syntrophin Mutation and the Long-QT Syndrome

Mutation Analysis of Potassium Channel Genes KCNQ1 and KCNH2 in Patients with Long QT Syndrome

A Novel Splice Mutation of HERG in a Chinese Family with Long QT Syndrome.

Three Novel Mutations of Potassium Channel HERG and SCN5A in Chinese Families of Congenital Long QT Syndromes

Characterization Of A Kcnq1/Kvlqt1 Polymorphism In Asian Families With Lqt2: Implications For Genetic Testing

Protective effect of <it>KCNH2 </it>single nucleotide polymorphism K897T in LQTS families and identification of novel <it>KCNQ1 </it>and <it>KCNH2 </it>mutations

Abstract Sa906: Topological Distribution of KCNH2 Variants and Genotype-Phenotype Relationship in Patients with Long QT Syndrome

Long QT Syndrome in Adults